^
Association details:
Biomarker:No biomarker
Cancer:Soft Tissue Sarcoma
Drug:Recentin (cediranib) (VEGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Excerpt:
Summary of recommendations...There is anecdotal evidence of activity of several molecular targeted agents: Sunitinib and cediranib in alveolar soft part sarcoma, where the molecular target is as yet unclear [IV, C].
DOI:
10.1093/annonc/mdy310